drugset / Trial / NCT00002824

Gene Therapy in Treating Patients With Primary Brain Tumors

NCT00002824

Treatment

Summary

RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients with primary brain tumors.

Timeline

Start
1996-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE Unknown Other
Background Ganciclovir Small molecule Intravenous